Taysha Gene Therapies, Inc.
TSHANASDAQHealthcare● Active
$5.43
$-0.07(-1.27%)
Market Cap$1.4B
P/E Ratio—
52W High$7.3
52W Low$2.25
Taysha Gene Therapies, Inc. (TSHA) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
TSHA · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 6, 2026EPS Actual
-$0.12
Est. -$0.10 · -20.0%
Revenue
—
Est. $0.00B
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 6, 2026
After Market Close
▼ Miss EPS
TSHA reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.21
Rev. $0.66B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.21
Rev. Est.$0.66B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 11, 2026 | -$0.11 | — | — | — | $0.00B | — |
| ▼ Q2 FY2026 | May 6, 2026 | -$0.10 | -$0.12 | -20.0% | — | $0.00B | — |
| ▲ Q1 FY2026 | Mar 19, 2026 | -$0.11 | -$0.08 | +27.3% | $0.01B | $0.00B | +144.5% |
| — Q4 FY2025 | Nov 4, 2025 | -$0.09 | -$0.09 | +0.0% | — | $0.00B | — |
| ▼ Q3 FY2025 | Aug 12, 2025 | -$0.07 | -$0.09 | -28.6% | $0.00B | $0.00B | +14.9% |
| — Q2 FY2025 | May 15, 2025 | -$0.08 | -$0.08 | +0.0% | $0.00B | $0.00B | +112.3% |
| ▲ Q1 FY2025 | Feb 26, 2025 | -$0.08 | -$0.07 | +12.5% | $0.00B | $0.00B | -1.5% |
| ▼ Q4 FY2024 | Nov 13, 2024 | -$0.08 | -$0.09 | -12.5% | $0.00B | $0.00B | -12.9% |
Q3 FY2026
Aug 11, 2026
EPS Actual
—
EPS Est.
-$0.11
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 6, 2026Miss
EPS Actual
-$0.12
EPS Est.
-$0.10
EPS Surpr.
-20.0%
Revenue
—
Q1 FY2026
Mar 19, 2026Beat
EPS Actual
-$0.08
EPS Est.
-$0.11
EPS Surpr.
+27.3%
Revenue
$0.01B
Q4 FY2025
Nov 4, 2025
EPS Actual
-$0.09
EPS Est.
-$0.09
EPS Surpr.
+0.0%
Revenue
—
Q3 FY2025
Aug 12, 2025Miss
EPS Actual
-$0.09
EPS Est.
-$0.07
EPS Surpr.
-28.6%
Revenue
$0.00B
Q2 FY2025
May 15, 2025
EPS Actual
-$0.08
EPS Est.
-$0.08
EPS Surpr.
+0.0%
Revenue
$0.00B
Q1 FY2025
Feb 26, 2025Beat
EPS Actual
-$0.07
EPS Est.
-$0.08
EPS Surpr.
+12.5%
Revenue
$0.00B
Q4 FY2024
Nov 13, 2024Miss
EPS Actual
-$0.09
EPS Est.
-$0.08
EPS Surpr.
-12.5%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.00 | $0.00 | $0.00 | 2 |
| Q3 FY2027 | $-0.09 | $-0.09 | $-0.09 | 1 |
| Q2 FY2027 | $-0.13 | $-0.13 | $-0.13 | 1 |
| Q1 FY2027 | $-0.13 | $-0.13 | $-0.13 | 2 |
| Q4 FY2026 | $-0.12 | $-0.12 | $-0.12 | 2 |
| Q3 FY2026 | $-0.13 | $-0.12 | $-0.11 | 4 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.1B | $0.1B | $0.1B | 6 |
| Q3 FY2027 | $0.1B | $0.1B | $0.1B | 6 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 6 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 6 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 11 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 12 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 6, 2026 | -20.0% | $6.94 | $6.98 | +0.58% |
| ▲ Q1 FY2026 | Mar 19, 2026 | +27.3% | $4.45 | $4.56 | +2.47% |
| ▲ Q4 FY2025 | Nov 4, 2025 | +0.0% | $4.46 | $4.27 | -4.26% |
| ▼ Q3 FY2025 | Aug 12, 2025 | -28.6% | $2.76 | $2.91 | +5.43% |
| ▲ Q2 FY2025 | May 15, 2025 | +0.0% | $2.37 | $2.56 | +8.02% |
| ▲ Q1 FY2025 | Feb 26, 2025 | +12.5% | $1.70 | $1.62 | -4.71% |
| ▼ Q4 FY2024 | Nov 13, 2024 | -12.5% | $2.39 | $2.21 | -7.53% |
| ▲ Q3 FY2024 | Aug 12, 2024 | +10.0% | $2.09 | $2.04 | -2.39% |
Q2 FY2026+0.58%
Report Date
May 6, 2026
EPS Beat/Miss
-20.0%
Price Before
$6.94
Price After
$6.98
Q1 FY2026+2.47%
Report Date
Mar 19, 2026
EPS Beat/Miss
+27.3%
Price Before
$4.45
Price After
$4.56
Q4 FY2025-4.26%
Report Date
Nov 4, 2025
EPS Beat/Miss
+0.0%
Price Before
$4.46
Price After
$4.27
Q3 FY2025+5.43%
Report Date
Aug 12, 2025
EPS Beat/Miss
-28.6%
Price Before
$2.76
Price After
$2.91
Q2 FY2025+8.02%
Report Date
May 15, 2025
EPS Beat/Miss
+0.0%
Price Before
$2.37
Price After
$2.56
Q1 FY2025-4.71%
Report Date
Feb 26, 2025
EPS Beat/Miss
+12.5%
Price Before
$1.70
Price After
$1.62
Q4 FY2024-7.53%
Report Date
Nov 13, 2024
EPS Beat/Miss
-12.5%
Price Before
$2.39
Price After
$2.21
Q3 FY2024-2.39%
Report Date
Aug 12, 2024
EPS Beat/Miss
+10.0%
Price Before
$2.09
Price After
$2.04
Avg Beat Reaction-0.17%
Avg Miss Reaction-0.51%
Beat Rate5 / 8 quarters
Largest Move+8.02% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: TSHA ends December
Taysha Gene Therapies, Inc. (TSHA) most recently reported earnings on May 6, 2026 for Q2 FY2026, posting EPS of $-0.12 — missing the analyst consensus of $-0.10 by -20.0%. The next TSHA earnings date is expected around September 1, 2026.
Each quarter, investors track TSHA earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. TSHA revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
TSHA's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
TSHA earnings · 5 questionsTaysha Gene Therapies, Inc.'s next earnings report is expected around September 1, 2026. TSHA typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; TSHA historically reports after market close (AMC).
TSHA earnings datewhen is TSHA earningsTSHA next earnings datewhen does TSHA report earningsTSHA earnings calendar
▸ Source: FMP · Taysha Gene Therapies, Inc. SEC filings · US GAAP · Taysha Gene Therapies, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026